EQL Pharma AB (publ) (STO:EQL)

EQL Pharma AB Revenue

EQL Pharma AB had revenue of 107.22M SEK in the quarter ending June 30, 2025, with 29.50% growth. This brings the company's revenue in the last twelve months to 397.94M, up 36.87% year-over-year. In the fiscal year ending March 31, 2025, EQL Pharma AB had annual revenue of 373.52M with 41.39% growth.

• Revenue (ttm): 397.94M
• Revenue Growth: +36.87%
• P/S Ratio: 4.50
• Revenue / Employee: 19.90M
• Employees: 21
• Market Cap: 1.79B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Mar 31, 2025	373.52M	109.35M	41.39%
Mar 31, 2024	264.17M	4.26M	1.64%
Mar 31, 2023	259.91M	-149.84M	-36.57%
Mar 31, 2022	409.75M	230.61M	128.73%
Mar 31, 2021	179.14M	107.11M	148.70%